
Index

A,B

- Antibody neutralization, hepatitis C virus pseudo-particle assay, 192, 193
- Baculovirus expression system, *see* Severe acute respiratory syndrome coronavirus
- Bunyamwera virus
 - Bunyaviridae* features, 137, 138
 - glycoprotein analysis
 - cell lysate preparation
 - gel electrophoresis samples, 143
 - immunoprecipitation samples, 144, 146
 - double immunofluorescence staining with Golgi markers
 - sample preparation, 141, 142
 - staining, 142, 146
 - immunoprecipitation, 144, 146
 - materials, 138, 139
 - metabolic radiolabeling, 142, 143, 146
 - overview, 138
 - recombinant virus preparation, 144–146
 - vaccinia virus expression system, 139, 140, 146

D

- DC-SIGN
 - cell type distribution, 51, 52
 - gp120 binding, 53
 - structure, 52–54
 - virus binding and function studies
 - binding assay, 62–65
 - dendritic cell expression
 - monocyte isolation, 60
 - peripheral blood mononuclear cell isolation, 60

- infection studies, 63–65
- internalization assay, 62, 63
- materials, 55–60, 64, 65
- overview, 53–55
- Semliki forest virus particles
 - soluble glycoprotein
 - production, 61, 62, 64, 65
 - titration, 61
 - transfection, 61, 64

- Dengue virus envelope glycoprotein genome, 163
- Pichia pastoris* expression system
 - advantages, 164
 - detection of secretion, 169
 - glycosylation analysis
 - endoglycosidase H, 170–172
 - PNGase F, 170–172
 - materials, 164, 165
 - transformation, growth, and induction, 168, 169, 174
 - vectors, 166, 167, 174
 - virus-like particles
 - co-expression with proteins, 172
 - electron microscopy, 173
 - immunofluorescence assay, 173
 - sucrose gradient centrifugation, 172, 173, 175
 - virion structure, 163

- Dextran sulfate, respiratory syncytial virus–glycosaminoglycan interaction competition studies, 23, 24

E

- Electron microscopy
 - Dengue virus-like particles, 173
 - severe acute respiratory syndrome virus-like particles, 44–46

- ELISA, *see* Enzyme-linked immunosorbent assay
- Endoglycosidase F1, glycan structure analysis, 11
- Endoglycosidase F2, glycan structure analysis, 11
- Endoglycosidase F3, glycan structure analysis, 11
- Endoglycosidase H
- Dengue virus envelope protein glycosylation analysis, 170–172
 - respiratory syncytial virus fusion protein analysis
 - baculovirus-expressed glycoprotein, 158
 - maturation status, 76, 77
 - severe acute respiratory syndrome coronavirus spike glycoprotein analysis, 132–134
 - spike glycoprotein analysis from severe acute respiratory syndrome coronavirus, 132–134
 - substrate specificity, 10, 11
- Envelope glycoprotein, *see* Dengue virus envelope glycoprotein
- Enzyme-linked immunosorbent assay (ELISA)
- hemagglutinin expressed using recombinant vaccinia virus, 91, 92
 - hepatitis C virus glycoproteins, 188
- F**
- FACE, *see* Fluorophore-assisted carbohydrate electrophoresis
- Flow cytometry, respiratory syncytial virus studies
- fusion protein cell surface transport, 77–79, 81
 - infection of glycosaminoglycan-deficient cells, 20, 21, 30
- Fluorophore-assisted carbohydrate electrophoresis (FACE), principles, 9
- Fusion protein, respiratory syncytial virus
- baculovirus expression system
 - glutathione *S*-transferase fusion protein glycosylation status, 156–158
 - immunofluorescence assay, 154–156, 160
 - materials, 150, 151
 - recombinant virus expression, 151, 153, 154, 158–160
 - glycosylation role in paramyxoviruses, 2
 - heterogeneity analysis by two-dimensional gel electrophoresis, 103, 107
 - α -mannosidase inhibitor effects, 103, 105
 - materials, 98, 99
 - membrane isolation, 102
 - processed forms, 97, 98
 - pulse-chase labeling, 100, 101
 - sample preparation, 102, 105, 107
- N*-linked glycan analysis
- endoglycosidase H digestion for maturation status analysis, 76, 77
 - flow cytometry of cell surface transport, 77–79, 81
 - functional overview, 69–71
 - immunoprecipitation, 74, 75
 - materials, 71, 72
 - radiolabeling, 73, 74
 - site-directed mutagenesis, 72–76
 - syncytial formation assay, 79–82
 - vaccinia virus T7 expression system, 73, 81, 82
 - posttranslational processing, 150
- G**
- G glycoprotein, respiratory syncytial virus
- antigenicity, 115
 - glycan characterization

- cell extract preparation, 116, 121
 - lectins
 - precipitation, 118, 119, 121
 - specificities, 113
 - materials, 115, 116
 - monoclonal antibodies
 - immunoprecipitation, 118
 - specificities, 113, 114
 - Western blot analysis, 117, 118, 121
 - overview, 112, 115
 - glycosylation sites, 110
 - proteolytic digestion, 120, 122
 - purification
 - glutathione *S*-transferase fusion protein expression and purification, 120–123
 - immunoaffinity chromatography, 119–122
 - immunoaffinity column preparation, 116, 117
 - structure, 114, 115
 - Glycophosphatidylinositol (GPI)
 - anchor, examples, 8
 - Glycosaminoglycans, *see also specific glycosaminoglycans*
 - biosynthesis, 17
 - protein interactions, 16
 - respiratory syncytial virus
 - interactions
 - clinical virus sample evaluation, 28–30
 - glycosaminoglycan identification
 - competition studies, 22
 - glycosaminoglycan removal, 21, 22
 - glycosaminoglycan sulfation role studies
 - dextran sulfate competition, 23, 24
 - protamine sulfate competition, 25
 - sodium chlorate inhibition of sulfation, 24
 - sulfation-deficient cell line infection, 24, 25
 - green fluorescent protein as marker, 17
 - heparan sulfate structure analysis
 - acetylated heparan sulfate studies, 25, 26
 - iduronic acid blocking with fibroblast growth factor-2, 26, 27
 - minimal chain size determination, 26
 - infection of glycosaminoglycan-deficient cells
 - Chinese hamster ovary cell infection, 19, 20, 30
 - flow cytometry, 20, 21, 30
 - infectivity role, 17, 18, 30
 - materials, 18
 - overview, 16
 - virion-associated
 - glycosaminoglycan radiolabeling with sulfur-35, 27, 28
 - structure, 15
 - gp120
 - DC-SIGN binding, 53
 - glycosylation sites, 110
 - immune response, 114
 - GPI anchor, *see* Glycophosphatidylinositol anchor
- ## H
- HCV, *see* Hepatitis C virus
 - Hemagglutinin, expression using recombinant vaccinia virus
 - enzyme-linked immunosorbent assay, 91, 92
 - large-scale preparation, 92, 93
 - materials, 86, 87
 - overview, 85, 86
 - recombinant virus preparation, 87–89, 93, 94

virus working stock preparation and titration, 90, 91, 94
 Western blot, 89, 90, 94
 Heparan sulfate
 structure analysis in respiratory syncytial virus–glycosaminoglycan interaction
 acetylated heparan sulfate studies, 25, 26
 minimal chain size determination, 26
 iduronic acid blocking with fibroblast growth factor-2, 26, 27
 virus attachment role, 2, 8, 16
 Hepatitis C virus (HCV)
 classification, 178
 genome, 177
 glycoprotein characterization
 enzyme-linked immunosorbent assay, 188
 immunoprecipitation, 188, 189
 transfection, 186, 195
 Western blot, 187
 glycoprotein gene cloning
 cloning of amplified genes, 183–186
 complementary DNA synthesis, 180–182, 194, 195
 polymerase chain reaction, 182, 183, 194, 195
 serum collection for viral RNA extraction, 179, 180, 194
 proteins and functions, 178
 pseudo-particle assay
 antibody neutralization, 192, 193
 materials, 178, 179
 principles, 189, 190, 195, 196
 sucrose gradient centrifugation, 191, 192
 target cell infection, 190, 191

I

Iduronic acid, blocking in
 glycosaminoglycans with fibroblast growth factor-2, 26, 27
 Influenza virus, hemagglutinin
 expression using recombinant vaccinia virus
 enzyme-linked immunosorbent assay, 91, 92
 large-scale preparation, 92, 93
 materials, 86, 87
 overview, 85, 86
 recombinant virus preparation, 87–89, 93, 94
 virus working stock preparation and titration, 90, 91, 94
 Western blot, 89, 90, 94

L

Lectins
 binding specificity and glycan structure analysis, 11–13
 C type lectins, *see* DC-SIGN; L-SIGN
 G glycoprotein analysis
 precipitation, 118, 119, 121
 specificities, 113
 L-SIGN
 cell type distribution, 52
 structure, 52–54
 virus binding and function studies
 binding assay, 62–65
 infection studies, 63–65
 internalization assay, 62, 63
 materials, 55–60, 64, 65
 overview, 53–55
 Semliki forest virus particles
 soluble glycoprotein production, 61, 62, 64, 65
 titration, 61
 transfection, 61, 64

M–P

α -Mannosidase, inhibitor effects on
respiratory syncytial virus
fusion protein, 103, 105

N-linked glycosylation, *see also*
Respiratory syncytial virus
consensus sequence, 3, 71
enzyme activities, 3, 4, 6, 7
structures, 3, 5, 6
virus distribution, 70

O-linked glycosylation
proteoglycans, 6
site prediction, 110
structures, 4, 5

Pichia pastoris expression system, *see*
Dengue virus envelope
glycoprotein

PNGase F
Dengue virus envelope protein
glycosylation analysis, 170–
172
respiratory syncytial virus fusion
protein analysis, 158
substrate specificity, 10

Protamine sulfate, respiratory syncytial
virus–glycosaminoglycan
interaction competition studies,
25

Pseudo-particle assay, *see* Hepatitis C
virus

R

Radiolabeled sugars, glycoprotein
detection, 8–9

Respiratory syncytial virus (RSV)
fusion protein heterogeneity analysis
by two-dimensional gel
electrophoresis
gel electrophoresis, 103, 107
 α -mannosidase inhibitor effects,
103, 105
materials, 98, 99

membrane isolation, 102
processed forms, 97, 98
pulse–chase labeling, 100, 101
sample preparation, 102, 105, 107
fusion protein *N*-linked glycan
analysis
endoglycosidase H digestion for
maturation status analysis, 76,
77
flow cytometry of cell surface
transport, 77–79, 81
functional overview, 69–71
immunoprecipitation, 74, 75
materials, 71, 72
radiolabeling, 73, 74
site-directed mutagenesis, 72–76
syncytial formation assay, 79–82
vaccinia virus T7 expression
system, 73, 81, 82
G glycoprotein, *see* G glycoprotein
glycosaminoglycan interactions
clinical virus sample evaluation,
28–30
glycosaminoglycan identification
competition studies, 22
glycosaminoglycan removal,
21, 22
glycosaminoglycan sulfation role
studies
dextran sulfate competition,
23, 24
protamine sulfate competition,
25
sodium chlorate inhibition of
sulfation, 24
sulfation-deficient cell line
infection, 24, 25
green fluorescent protein as
marker, 17
heparan sulfate structure analysis
acetylated heparan sulfate
studies, 25, 26

- iduronic acid blocking with fibroblast growth factor-2, 26, 27
 - minimal chain size determination, 26
- infection of glycosaminoglycan-deficient cells
 - Chinese hamster ovary cell infection, 19, 20, 30
 - flow cytometry, 20, 21, 30
- infectivity role, 17, 18, 30
- materials, 18
- overview, 16
- virion-associated
 - glycosaminoglycan radiolabeling with sulfur-35, 27, 28
- strains, 115
- RSV, *see* Respiratory syncytial virus
- S**
- SARS, *see* Severe acute respiratory syndrome coronavirus
- Semliki forest virus, lectin binding, *see* DC-SIGN; L-SIGN
- Severe acute respiratory syndrome coronavirus
 - 3a protein and baculovirus expression system for virus-like particle formation
 - advantages, 35, 36
 - Bac-to-Bac system, 35
 - co-expression with M and E proteins, 43
 - materials, 37, 38
 - myc-3a recombinant virus generation
 - bacmid preparation, 39, 40, 46
 - bacmid transfection of insect cells, 41, 46, 47
 - cloning, 39, 46
 - vector, 38, 39
 - principles, 36, 37
 - viral infection and cell lysis, 42
 - virus-like particles
 - purification, 44, 47
 - transmission electron microscopy, 44-46
 - Western blot, 42
 - features, 36
 - spike glycoprotein
 - endoglycosidase H analysis, 132-134
 - function, 127, 128
 - gel electrophoresis and autoradiography, 131, 132
 - immunoprecipitation, 131, 135
 - materials, 128, 129
 - pulse-chase labeling, 141, 134, 135
 - structure, 128
 - vaccinia virus expression system
 - infection and transfection, 130
 - vector construction, 129, 130, 134
- S glycoprotein, *see* Spike glycoprotein
- Sodium chlorate, glycosaminoglycan sulfation inhibition, 24
- Spike (S) glycoprotein, severe acute respiratory syndrome coronavirus
 - endoglycosidase H analysis, 132-134
 - function, 127, 128
 - gel electrophoresis and autoradiography, 131, 132
 - immunoprecipitation, 131, 135
 - materials, 128, 129
 - pulse-chase labeling, 141, 134, 135
 - structure, 128
 - vaccinia virus expression system
 - infection and transfection, 130
 - vector construction, 129, 130, 134
- Sucrose gradient centrifugation
 - Dengue virus-like particles, 172, 173, 175
 - hepatitis C virus pseudo-particle assay, 191, 192

T–W

- Two-dimensional gel electrophoresis,
 - fusion protein heterogeneity analysis by two-dimensional gel electrophoresis, 103, 107
 - α -mannosidase inhibitor effects, 103, 105
 - materials, 98, 99
 - membrane isolation, 102
 - processed forms, 97, 98
 - pulse–chase labeling, 100, 101
 - sample preparation, 102, 105, 107
- Vaccinia virus expression system
 - Bunyamwera virus glycoproteins, 139, 140, 146
 - influenza hemagglutinin expression
 - enzyme-linked immunosorbent assay, 91, 92
 - large-scale preparation, 92, 93

- materials, 86, 87
 - overview, 85, 86
 - recombinant virus preparation, 87–89, 93, 94
 - virus working stock preparation and titration, 90, 91, 94
 - Western blot, 89, 90, 94
 - respiratory syncytial virus fusion
 - protein expression, 73, 81, 82
- Western blot
- Dengue virus envelope glycoprotein, 169
 - G glycoprotein analysis, 117, 118, 121
 - hemagglutinin expressed using recombinant vaccinia virus, 89, 90, 94
 - hepatitis C virus glycoproteins, 187
 - severe acute respiratory syndrome coronavirus 3a protein, 42